Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer

被引：6
|
作者：
Lin, Yi-Tsz
Chu, Chia-Yu
机构：
[1] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei 10002, Taiwan
[2] Natl Taiwan Univ, Coll Med, Taipei 10002, Taiwan
来源：
LUNG CANCER | 2019年 / 129卷
关键词：
DRUG CAUSALITY; NECROLYSIS;
D O I：
10.1016/j.lungcan.2018.12.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：110 / 111
页数：2
相关论文
共 50 条
  • [1] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [2] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [3] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
  • [4] An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer
    Wang, Jingyi
    Wu, Lin
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (06) : 647 - 652
  • [5] Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation
    Imamura, Fumio
    Kimura, Madoka
    Yano, Yukihiro
    Mori, Masahide
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Ihara, Shouichi
    Komuta, Kiyoshi
    Shiroyama, Takayuki
    Nagatomo, Izumi
    Kumagai, Toru
    [J]. FUTURE ONCOLOGY, 2020, 16 (21) : 1537 - 1546
  • [6] Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
    Makimoto, Go
    Nishi, Tatsuya
    Kawakado, Keita
    Nishimura, Tomoka
    Tamura, Tomoki
    Kudo, Kenichiro
    Kuyama, Shoichi
    [J]. INTERNAL MEDICINE, 2020, 59 (17) : 2161 - 2164
  • [7] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status
    Nakashima, Kazuhisa
    Kimura, Madoka
    Akamatsu, Hiroaki
    Daga, Haruko
    Imai, Hisao
    Taira, Tetsuhiko
    Ko, Ryo
    Hisamatsu, Yasushi
    Nishino, Kazumi
    Sugimoto, Takeya
    Miyashita, Yosuke
    Takahashi, Toshiaki
    Kumagai, Toru
    Yamamoto, Nobuyuki
    Murakami, Haruyasu
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (07) : 671 - 675
  • [8] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [9] Differential efficacy of Osimertinib in EGFR T790M positive non-small cell lung cancer by metastatic site
    Uematsu, Shinya
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
  • [10] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer who have poor performance status
    Kimura, Madoka
    Nishino, Kazumi
    Imamura, Fumio
    Nakashima, Kazuhisa
    Takahashi, Toshiaki
    Sugimoto, Takeya
    Akamatsu, Hiroaki
    Yamamoto, Nobuyuki
    Daga, Haruko
    Imai, Hisao
    Taira, Tetsuhiko
    Miyashita, Yosuke
    Ko, Ryo
    Hisamatsu, Yasushi
    Murakami, Haruyasu
    [J]. ANNALS OF ONCOLOGY, 2018, 29
12345